I Just Landed on Earth and Read About ‘Reproductive Health Care.’ I Have Questions.
Imagine you just arrived on Earth. No prior exposure to American medical politics. No tribal loyalties. No career to protect.
You read that a major medical organization has declared a Digital Day of Action.
The message: “Defending reproductive health care means defending access to mifepristone.”
Your first question, entirely reasonable, entirely innocent: what is reproductive health care?
Here is what the term actually covers.
Reproductive health care is the full range of medical services related to the human reproductive system. Prenatal care. Labor and delivery. Postpartum recovery. Contraception. Fertility treatment. Miscarriage management. Ectopic pregnancy treatment. Abortion. Cervical and ovarian cancer screening. STI testing and treatment. Menopause management. Pelvic floor disorders.
It is most of what an obstetrician-gynecologist does across a patient’s entire life.
So your second question, still innocent, still reasonable: does all of that depend on one specific medication? Mifepristone?
The answer is no.
The alien has just found the problem.
Prenatal care does not depend on mifepristone. Fertility treatment does not depend on mifepristone. Cervical cancer screening does not depend on mifepristone. Mifepristone is used for medical abortion and miscarriage management. It is one drug within a very large category.
You identified that in about 90 seconds.
American organized medicine has avoided it for 25 years.
ACOG uses the phrase. ACOG does not define it.
Search ACOG’s website. You will find “reproductive health care” in hundreds of statements, position papers, and press releases. You will not find a formal clinical definition with boundaries.
ACOG’s stated position is that abortion is an essential component of comprehensive medical care and that patients need access to the full spectrum of reproductive health care options. The “full spectrum” is invoked constantly. It is never mapped.
A professional organization that sets evidence standards for an entire specialty should be able to define its own operating terms.
Why this matters beyond semantics.
When “reproductive health care” is used as a rhetorical container rather than a clinical category, it does two things simultaneously.
It signals, appropriately, that the term covers far more than any single procedure or medication.
And it allows any single element within that undefined category to carry the full moral and political weight of the entire category.
Every patient who has ever received prenatal care, an IUD, or a Pap smear is implicitly recruited into the defense of one specific drug. That may be effective advocacy. It is not precise medicine.
The mifepristone case stands on its own evidence.
Mifepristone has a well-established safety record. The FDA approved it in 2000. Decades of post-marketing data confirm that profile. The case for protecting access is strong.
Make that case. Lead with the safety data. Lead with what happens to patients when access is restricted.
The evidence is strong enough to stand without an undefined umbrella term doing the heavy lifting.
While we are talking about access: where is the Digital Day of Action for equal access to an OB-GYN?
Here is the alien’s third question, still innocent, still devastating: if ACOG can mobilize a national day of action to protect one medication, why has there been no Digital Day of Action to ensure that every woman in America, regardless of insurance status or race, has equal access to an obstetrician-gynecologist?
The data are not ambiguous.
The numbers.
OB-GYNs accept new Medicaid patients at a rate of 81.7%. They accept new privately insured patients at 98.9%. That 17-point gap represents millions of women who cannot get an appointment at the same practice a commercially insured woman can call tomorrow.
Medicaid covers more than 4 in 10 births in the United States. It covers 65% of all births to Black mothers. It covers 30% of Black reproductive-age women and 26% of Hispanic reproductive-age women, compared to 20% of reproductive-age women overall.
The arithmetic is straightforward. Insurance discrimination in OB-GYN access is racial discrimination in OB-GYN access. The two cannot be separated.
Where Medicaid patients actually go.
Private OB-GYN practices accept Medicaid at 77%. Community health centers accept Medicaid at 90%. As a result, nearly half of Medicaid patients receive OB-GYN care at community health centers, while only about one in four patients at private practices is on Medicaid.
The system has sorted women into a two-tier architecture: privately insured women see private physicians; Medicaid patients go to clinics. ACOG members built that architecture. Approximately one-third of ACOG members have made changes to their practices specifically to limit or eliminate Medicaid patients.
This is not an accusation. It is what the survey data show.
The consequences are not hypothetical.
Black women die from pregnancy-related causes at more than 3 times the rate of white women. Severe maternal morbidity is 2.1 times higher for Black women than for white women. These gaps do not exist in a vacuum. They exist in a system where the women at highest risk are the most likely to be denied access to a private OB-GYN practice.
Defending reproductive health care, if that phrase means anything, means defending equal access to the full category of care it supposedly describes. For every woman. At every practice. Regardless of what card she hands to the front desk.
The question ACOG has not answered.
Why does a Digital Day of Action exist for one medication used primarily by insured patients who can access a physician, but not for the structural barrier that prevents the most vulnerable women from accessing any obstetrician at all?
Mifepristone access and equal Medicaid access are not competing issues. Both matter. Both deserve mobilization.
The alien noticed the asymmetry immediately.
What I am asking for is consistency.
Define reproductive health care. Then defend all of it. For all women.
That is what evidence-based advocacy looks like.
The alien figured out both problems in about 90 seconds. We can do better.
#ObGynIntelligence #ReproductiveHealth #HealthEquity #Medicaid #MaternalHealth #ACOG #WomensHealth
My point was narrower: in obstetrics, we often mobilize loudly around symbolic or politically safe issues, while unequal access to basic prenatal and obstetric care remains under-mobilized. Naming the historical causes is important, but it does not absolve today’s professional organizations from asking why access to an obstetrician-gynecologist is still not treated as an urgent women’s health priority. Only about 64% of eligible Americans voted in the last presidential election. That means more than one-third did not vote, which is part of the problem when we speak about what “America” believes or supports.
The United States is the only wealthy industrialized nation without universal health coverage, in large part thanks to racist policies propagated by the AMA over decades upon decades, which embedded arguments against "socialized medicine" framing so deeply that they continue to constrain the range of politically acceptable health policy debate today. Amos, have you been to a doctor's lounge in a hospital? What channel is inevitably on? As someone who has worked in rural, small community, suburban, urban, and academic tertiary care centers, I can tell you that only the latter is less likely to be watching FOX News. This country elected Donald J. Trump and Ronald Reagan twice. You ask, somewhat coyly, "Why has there been no Digital Day of Action to ensure that every woman in America, regardless of insurance status or race, has equal access to an obstetrician-gynecologist?" Have you read Dying of Whiteness or The Sum of Us? Given your age, you, more than most, can remember the fervor with which anti-communist and anti-socialist and racist propaganda has bombarded the airways in this country for nearly a century. You strike me as an erudite man, so I'm confused as to why you don't offer your readers the answers to these rhetorical questions.